Month: May 2022

Statkraft discloses first quarter results 2022 on Wednesday 11 May 2022 at 08:00 a.m. CEST. The material will be available on Statkraft’s website www.statkraft.com/ir and Oslo Stock Exchange’s news service www.newsweb.no. Live webcast09:00 a.m. CEST: Statkraft presents the results in a live webcast at www.statkraft.com. The presentation will be held in English and is open for investors, analysts and media at Statkraft’s head office, Lilleakerveien 6, Oslo. To attend the presentation in Oslo, please send your registration to arild.ratikainen@statkraft.com. Contact:Arild Ratikainen, Investor Contact, tlf.: +47 971 74 132, e-mail: arild.ratikainen@statkraft.com This information is subject to the disclosure requirements pursuant to Section 5-12 the Norwegian Securities Trading Act

– Cash runway extended into 2024 – – Strengthened financial position with achievement of $30 million milestone from GlaxoSmithKline and $21 million raised in the quarter through ATM facility –            – Expanding open label lead-in for SRF388 in first-line hepatocellular carcinoma (HCC), with initial data expected in the first half of 2023 – – New SRF388 clinical data to be presented at 2022 American Society of Clinical Oncology (ASCO) Annual Meeting – CAMBRIDGE, Mass., May 09, 2022 (GLOBE NEWSWIRE) — Surface Oncology (Nasdaq: SURF), a clinical-stage immuno-oncology company developing next-generation immunotherapies that target the tumor microenvironment, reported financial results and corporate highlights for the first quarter of 2022 as well as upcoming anticipated corporate milestones. “The first quarter of 2022 marked the...

FDA review of NDA for FT218 continues; launch readiness preparations on-track to support potential commercial launchPresented interim results from ongoing RESTORE open-label extension / switch study of FT218 highlighting overwhelming patient preference for the once-at-bedtime dosing regimen and characterizing the burden associated with the second dose currently required for twice-nightly oxybatesManagement to host a conference call today at 8:30 a.m. ETDUBLIN, Ireland, May 09, 2022 (GLOBE NEWSWIRE) — Avadel Pharmaceuticals plc (Nasdaq: AVDL), a biopharmaceutical company focused on transforming medicines to transform lives, today provided a corporate update, and announced its financial results for the first quarter ended March 31, 2022. “As our NDA for FT218 continues in late-stage review, we stand at a pivotal moment for...

Total Net Sales of $433 million; Comparable Sales increased 2.1% versus prior year GAAP Net Loss of $26.9 million; Adjusted EBITDA of $4.6 million ELMSFORD, N.Y., May 09, 2022 (GLOBE NEWSWIRE) — Party City Holdco Inc. (the “Company” or “PRTY”; NYSE:PRTY) today announced financial results for the quarter ended March 31, 2022. Brad Weston, Chief Executive Officer of Party City, stated, “We are pleased to deliver another quarter of topline growth with a sales increase of 1.4% and brand comp sales growth of 2.1%, despite a difficult consumer backdrop with the Omicron variant earlier in the quarter. As expected, our bottom line results were impacted by elevated costs, including greater than anticipated freight and commodity cost pressures that ramped later in the quarter. Amidst this choppy macro environment, our teams are doing a...

Q1 2022 net income was $3.47 per basic and $3.41 per diluted share and adjusted non-GAAP net income* was $4.10 per basic and $4.04 per diluted share Q1 2022 total revenue was $115.9 million, up from $41.2 million in Q1 2021 Achieved sales of $34.3 million of vasopressin, with prior four weeks average market share of 24% per IQVIA data Achieved sales of $37.2 million of PEMFEXY™ (pemetrexed for injection), a branded alternative to ALIMTA® Agreed to terms to acquire Acacia Pharma Group plc, including two FDA-approved, NCE hospital-based products; expected to close in June 2022, subject to satisfaction of closing conditions Remains on track to support submission of new drug application later this month for landiolol, a beta-1 adrenergic blocker Expects to start clinical trial in CAL02 patients in Q3 2022 during pneumonia season Key objective...

BEAM-101 Patient Enrollment, BEAM-102 and BEAM-201 IND Submissions and BEAM-301 IND-Enabling Studies All On-track for Second Half of 2022 Natural History Study Initiated in People with Sickle Trait to Provide Insights into Key Characteristics of Sickle Cell Trait and Sickle Cell Disease Manmohan Singh, Ph.D., Appointed to Executive Leadership Team, and Anne Marie Woodland Appointed as Head of Regulatory Ended First Quarter 2022 with $1.2 Billion in Cash, Cash Equivalents and Marketable Securities to Support Advancement of Precision Genetic Medicines Portfolio CAMBRIDGE, Mass., May 09, 2022 (GLOBE NEWSWIRE) — Beam Therapeutics Inc. (Nasdaq: BEAM), a biotechnology company developing precision genetic medicines through base editing, today announced pipeline and business highlights and financial results for the first quarter ended...

MAESTRO-NAFLD-1 late-breaker and three other Madrigal abstracts accepted for oral presentation at the EASL International Liver Congress™ Data from the Phase 3 MAESTRO-NAFLD-1 study continue to reinforce the safety and efficacy profiles of resmetirom Madrigal remains on track to disclose topline data from MAESTRO-NASH in the fourth quarter and anticipates filing for accelerated approval under Subpart H next year Planned MAESTRO-NASH Outcomes trial, a non-invasive Phase 3 study designed to accelerate the full approval timeline for non-cirrhotic NASH, will evaluate resmetirom effects on liver decompensation events in patients with early NASH cirrhosis Madrigal enters into term loan facility with ability to draw up to $250 million to support expansion of clinical development program and preparation for a potential U.S. launch of resmetiromCompany...